The Effect of Tolbutamide on Human Basal Gastric Secretion

Article1 September 1961The Effect of Tolbutamide on Human Basal Gastric SecretionALEX WEISS, M.D., WILLIAM J. SCIALES, M.D.ALEX WEISS, M.D.Search for more papers by this author, WILLIAM J. SCIALES, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-55-3-406 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe suspicion that a new therapeutic agent may have ulcerogenic potentialities is a matter of great practical concern to the physician. The belief that compounds like the salicylates, steroids, ACTH, and phenylbutazone may induce peptic ulceration by stimulating acid secretion or by diminishing gastroduodenal tissue resistance in susceptible individuals has facilitated the institution of preventive measures, when use of the drug is unavoidable and when the expected benefit warrants the risk involved (1-3).Up to the present, little has been written in this regard concerning the oral antidiabetic agent, tolbutamide, a sulfonylurea compound with hypoglycemic effects (4-6). In general, few...References1. KIRSNER JB: Drug induced peptic ulcer. Ann. Intern. Med. 47: 666, 1957. LinkGoogle Scholar2. LAMBERT R: Les Aspects Recents de l'Ulcere Experimental, Librairie Arnette, Paris, 1958. Google Scholar3. SEGAL HL: Ulcerogenic drugs and technics: experimental and clinical. Amer. J. Med. 29: 780, 1960. CrossrefMedlineGoogle Scholar4. LAUBATIERES A: Mechanism of action of hypoglycemic sulfonamides. Concept based on investigation in animals and man. Diabetes 6: 408, 1957. CrossrefMedlineGoogle Scholar5. ASHMORECAHILLEARLEZOTTU JGFSAS: Studies on disposition of blood glucose. Comparison of insulin and Orinase. Diabetes 7: 1, 1958. CrossrefMedlineGoogle Scholar6. WEBERCAUTERO GA: Effect of Orinase on hepatic enzymes involved in glucose-6-phosphate utilization. Metabolism 7: 333, 1958. MedlineGoogle Scholar7. BAIRDHULL RWJG: Cholestatic jaundice from tolbutamide. Ann. Intern. Med. 53: 194, 1960. LinkGoogle Scholar8. BRADLEY RF: Role of oral blood sugar lowering agents in the management of diabetes. Ann. N. Y. Acad. Sci. 82: 513, 1959. CrossrefMedlineGoogle Scholar9. BROD RC: Blood dyscrasias associated with tolbutamide therapy. J. A. M. A. 171: 296, 1959. CrossrefMedlineGoogle Scholar10. MEHNERTCAMERINI-DAVALOSMARBLE HRA: Results of long term use of tolbutamide in diabetes mellitus. J. A. M. A. 167: 818, 1958. CrossrefMedlineGoogle Scholar11. BEASER SB: The use of Orinase in diabetes. Metabolism 5: 933, 1956. MedlineGoogle Scholar12. BEASER SB: Further experiences with the use of sulfonylureas in diabetes. Ann. N. Y. Acad. Sci. 71: 264, 1957. CrossrefMedlineGoogle Scholar13. GELFAND ML: Gastrointestinal bleeding during tolbutamide therapy. J. A. M. A. 171: 258, 1959. CrossrefMedlineGoogle Scholar14. JOSLINROOTWHITEMARBLE EPHFPA: Treatment of Diabetes Mellitus, 10th Ed., Lea & Febiger, Philadelphia, 1959, p. 467. Google Scholar15. UNGERMADISON RHLL: A new diagnostic procedure for mild diabetes mellitus. Diabetes 7: 455, 1958. CrossrefMedlineGoogle Scholar16. UNGERMADISON RHLL: Comparison of responses to intravenously administered sodium tolbutamide in mild diabetic and non-diabetic subjects. J. Clin. Invest. 37: 627, 1958. CrossrefMedlineGoogle Scholar17. FAJANSCONN SSJW: An intravenous tolbutamide test as an adjunct in the diagnosis of functioning pancreatic islet cell adenoma. J. Lab. Clin. Med. 54: 811, 1959. Google Scholar18. BUCHERGROSSMANIVY GRMIAC: Pepsin method: rate of dilution in determination of peptic activity. Gastroenterology 5: 501, 1945. MedlineGoogle Scholar19. ANSONMIRSKY MLAE: Estimation of pepsin with hemoglobin. J. Gen. Physiol. 16: 59, 1932. CrossrefMedlineGoogle Scholar20. ANSON ML: The estimation of pepsin, trypsin, papain, and cathepsin with hemoglobin. J. Gen. Physiol. 22: 79, 1938. CrossrefMedlineGoogle Scholar21. MAINLAND D: Elementary Medical Statistics, (Appendix), W. B. Saunders Co., Philadelphia, 1952, p. 319. Google Scholar22. STEMPIENFRENCHDAGRADEMOVIUSPORTER SJJDAHJRW: The early and delayed phases of gastric acid secretion in response to insulin hypoglycemia. I. The hypoglycemic secretory responses in duodenal ulcer patients and non-ulcer subjects. Gastroenterology 34: 104, 1958. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ALEX WEISS, M.D.; WILLIAM J. SCIALES, M.D.Affiliations: Flushing, N. Y.Received for publication March 15, 1961.From the Department of Internal Medicine, Flushing Hospital and Dispensary, Flushing, N. Y.Requests for reprints should be addressed to Alex Weiss, M.D., 168-17 35th Avenue, Flushing 58, N. Y.*Medical Division, Department of Clinical Investigation, The Upjohn Company, Kalamazoo, Mich. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byChanges in efferent activities of the gastric vagus nerve by administration of glucose in the portal veinAction of Insulin on Some Other Organs and on DifferentiationZur Pharmakologie und Toxikologie der blutzuckersenkenden SulfonamideTolbutamide gastric analysisEffects of Continuous Insulin Infusions on Unstimulated Human Gastric SecretionREEVALUATION OF THE HOLLANDER TESTChlorpropamide overdose.Zur Problematik der exokrinen Pankreasreaktion nach intraven�ser Tolbutamid-Belastung bei Stoffwechselgesunden und DiabetikernDose dependence of insulin-stimulated gastric secretionPeptic UlcerOn the Question of a Pituitary-Adrenal Component in the Gastric Secretory Response to Insulin HypoglycemiaPankreasdastaseexkretion bei intraven�ser Tolbutamidbelastung 1 September 1961Volume 55, Issue 3 Page: 406-415 Keywords Hospital medicine Hypoglycemia Hypoglycemics Pathologists Peptic ulcers Research grants Salicylates Sodium Steroids Ulcers ePublished: 1 December 2008 Issue Published: 1 September 1961 PDF downloadLoading ...